Proton therapy under the microscope: huge study aims to prove its worth
NCT ID NCT07317245
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is gathering information from 500 cancer patients treated with proton therapy, a type of radiation that may cause fewer side effects than standard radiation. Researchers want to see how well it works in everyday practice and track any side effects. The goal is to build evidence that could make proton therapy available to more people.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- proton therapy
- What this could lead to
- If successful, this study could provide stronger evidence to expand access to proton therapy for more cancer types, potentially reducing side effects compared to standard radiation.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results depend on the quality of real-world data, which may have limitations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jan 2036
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
patients with indication to proton therapy treatment
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Solid tumors candidate to proton therapy, in particular, according to Italian regolamentations * Written informed consent for HU-PRO according to applicable legal and ethical requirements * Indication for proton therapy * ≥ 18 years old * ECOG PS (performance status scale) 0-2 Exclusion Criteria: * Age \< 18 years old * ECOG (performance status scale) \>3 * Life expectancy \< 3 months * Inability to provide informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
IRCCS Humanitas Research Hospital
RECRUITINGRozzano, Michigan, 20025, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Two-Drug combo aims to stall advanced breast cancer
- Blood thinner flush could boost tumor biopsy success
- Could a frailty score predict which older cancer patients survive intensive care?